Sugi Predict

Sugi Predict / Compounds / SCHEMBL5656608

SCHEMBL5656608

SCHEMBL5656608

C[C@H](N)C(=O)Oc1ccco1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP1 P03956 1/20 0.44
▸ MMP9 P14780 1/20 0.44
▸ MMP12 P39900 1/20 0.44
▸ TAAR1 Q96RJ0 1/20 0.41
▸ ALOX5 P09917 4/20 0.40
▸ ALDH1A1 P00352 5/20 0.39
▸ SLC1A3 P43003 1/20 0.36
▸ SLC1A2 P43004 1/20 0.36
▸ SLC1A1 P43005 1/20 0.36
▸ CES2 O00748 1/20 0.35
▸ CES1 P23141 1/20 0.35
▸ KMT2A Q03164 5/20 0.35
▸ POLB P06746 2/20 0.35
▸ PKM P14618 1/20 0.35
▸ PTPN1 P18031 1/20 0.35
▸ PTPN7 P35236 1/20 0.35
▸ BLM P54132 1/20 0.35
▸ ESR2 Q92731 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15670569 0.86 MMP1 (0.42) MMP1MMP9MMP12TAAR1ALOX5
SCHEMBL15671059 0.85 MMP1 (0.41) MMP1MMP9MMP12TAAR1ALOX5
SCHEMBL15670432 0.82 MMP1 (0.42) MMP1MMP9MMP12TAAR1ALOX5
SCHEMBL5041398 0.82 MMP1 (0.44) MMP1MMP9MMP12ALOX5ALDH1A1
SCHEMBL15670665 0.81 ALDH1A1 (0.41) MMP1MMP9MMP12ALOX5ALDH1A1
SCHEMBL8633653 0.79 MMP1 (0.42) MMP1MMP9MMP12ALOX5ALDH1A1
SCHEMBL15670418 0.79 MMP1 (0.42) MMP1MMP9MMP12ALOX5ALDH1A1
SCHEMBL15670510 0.79 MMP1 (0.42) MMP1MMP9MMP12ALOX5ALDH1A1
SCHEMBL4223881 0.78 MMP1 (0.41) MMP1MMP9MMP12ALOX5ALDH1A1
SCHEMBL29128596 0.78 MMP1 (0.41) MMP1MMP9MMP12ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3912641-B1 HYDROPHILIC DRUG-LINKER COMPOUNDS SEAGEN INC (US) 2024-11-06 — — EP claimed
US-20230132738-A1 HYDROPHILIC ANTIBODY-DRUG CONJUGATES SEAGEN INC (US) 2023-05-04 — — US claimed
US-11510959-B2 Hydrophilic antibody-drug conjugates SEAGEN INC. (US) 2022-11-29 — — US claimed
EP-3912641-A1 HYDROPHILIC DRUG-LINKER COMPOUNDS Seagen Inc. (US) 2021-11-24 — — EP claimed
US-20210283210-A1 HYDROPHILIC ANTIBODY-DRUG CONJUGATES SEAGEN INC (US) 2021-09-16 — — US claimed
EP-3107557-B1 HYDROPHILIC ANTIBODY-DRUG CONJUGATES SEAGEN INC (US) 2021-06-09 — — EP claimed
US-10933112-B2 Hydrophilic antibody-drug conjugates SEAGEN INC. (US) 2021-03-02 — — US claimed
US-20170216391-A1 HYDROPHILIC ANTIBODY-DRUG CONJUGATES SEATTLE GENETICS, INC. (US) 2017-08-03 — — US claimed
EP-3107557-A1 HYDROPHILIC ANTIBODY-DRUG CONJUGATES Seattle Genetics, Inc. (US) 2016-12-28 — — EP claimed
CN-106029083-A Hydrophilic antibody-drug conjugates 西雅图基因公司 2016-10-12 — — CN claimed
WO-2015123679-A1 HYDROPHILIC ANTIBODY-DRUG CONJUGATES SEATTLE GENETICS, INC. (US) 2015-08-20 — — WO claimed
CN-102223898-A Peptides for treatment of obesity NOVO NORDISK AS 2011-10-19 — — CN claimed
CN-101222942-A Peptides for use in the treatment of obesity NOVO NORDISK AS (DK) 2008-07-16 — — CN claimed
CN-120051565-A Engineered terminal deoxynucleotidyl transferase variants 科德克希思公司 2025-05-27 — — CN disclosed
US-12257281-B2 Hydrophilic antibody-drug conjugates SEAGEN INC. (US) 2025-03-25 — — US disclosed
CN-113396218-B Engineered transaminase polypeptides 科德克希思公司 2025-02-18 — — CN disclosed
CN-101384274-A Compositions comprising peptides having non-naturally occurring amino acids and methods of use thereof AVON PROD INC (US) 2009-03-11 — — CN disclosed
CN-101222942-A Peptides for use in the treatment of obesity NOVO NORDISK AS (DK) 2008-07-16 — — CN disclosed
US-20070093645-A1 Peptide vectors SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION (FR) 2007-04-26 — — US disclosed
CN-1297354-A Dipeptide caspase inhibitors and use thereof CYTOVIA INC (US) 2001-05-30 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210283210-A1 HYDROPHILIC ANTIBODY-DRUG CONJUGATES CD44, FCGR1A, FCGR2A MMP1 2117/4885MMP9 1633/4885MMP12 1487/4885
US-11510959-B2 Hydrophilic antibody-drug conjugates CD44, FCGR1A, FCGR2A MMP1 2117/4885MMP9 1633/4885MMP12 1487/4885
US-12257281-B2 Hydrophilic antibody-drug conjugates CD44, FCGR1A, FCGR2A MMP1 2117/4885MMP9 1633/4885MMP12 1487/4885
US-20170216391-A1 HYDROPHILIC ANTIBODY-DRUG CONJUGATES CD44, FCGR1A, FCGR2A MMP1 2117/4885MMP9 1633/4885MMP12 1487/4885
US-10933112-B2 Hydrophilic antibody-drug conjugates CD44, FCGR1A, FCGR2A MMP1 2117/4885MMP9 1633/4885MMP12 1487/4885
US-20070093645-A1 Peptide vectors TP53, VIP, XIAP MMP1 688/4885MMP9 686/4885MMP12 105/4885
US-20230132738-A1 HYDROPHILIC ANTIBODY-DRUG CONJUGATES CD44, FCGR1A, FCGR2A MMP1 2117/4885MMP9 1633/4885MMP12 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.